Quantitative Investment Management LLC Acquires 6,152 Shares of Natera, Inc. $NTRA

Quantitative Investment Management LLC grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 49.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,662 shares of the medical research company’s stock after acquiring an additional 6,152 shares during the quarter. Quantitative Investment Management LLC’s holdings in Natera were worth $3,004,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of NTRA. Sound Income Strategies LLC increased its position in Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares during the period. Quent Capital LLC bought a new stake in Natera in the 3rd quarter valued at $46,000. Hilltop National Bank boosted its holdings in Natera by 59.8% in the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 116 shares during the period. N.E.W. Advisory Services LLC grew its position in Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after purchasing an additional 226 shares during the last quarter. Finally, AXS Investments LLC acquired a new stake in Natera in the 3rd quarter worth $69,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced the commercial launch of its Zenith™ Genomics rare‑disease diagnostic product, marking a new commercial offering that could expand the company’s addressable market for clinical whole‑genome testing. Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
• Positive Sentiment: MyOme debuted the Zenith™ portfolio with Natera and launched long‑read methylation analysis at ACMG 2026 — a technology/commercial collaboration that could broaden Natera’s diagnostic capabilities (epigenetic and long‑read WGS) and improve clinical utility over time. MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
• Positive Sentiment: Market reaction in the space: competing specialist GeneDx reported a share drop after Natera’s launch, suggesting investors see the new product as competitive and potentially share‑grabbing in the rare‑disease testing market. This is an indirect validation of the commercial opportunity. GeneDx stock falls as Natera launches competing rare disease test
• Neutral Sentiment: Natera presented at the Leerink Global Healthcare Conference (transcript available). The presentation provides management commentary on product adoption, reimbursement and growth drivers — useful for modeling but not an immediate market catalyst on its own. Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Insider selling: CEO Steven Chapman sold ~5,623 shares and other senior insiders (CFO Michael Brophy, John Fesko, Solomon Moshkevich) also sold shares on the same date. Multiple concurrent insider sales are weighing on sentiment and likely contributed to today’s downward pressure. SEC Form 4 — CEO Sale

Natera Stock Performance

Shares of Natera stock opened at $190.31 on Friday. The firm has a market cap of $26.97 billion, a P/E ratio of -124.39 and a beta of 1.65. The firm’s 50-day simple moving average is $220.54 and its 200-day simple moving average is $205.96. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same quarter in the prior year, the business posted ($0.41) earnings per share. On average, equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 37,175 shares of the business’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50. Following the sale, the chief financial officer owned 64,123 shares of the company’s stock, valued at $15,552,392.42. The trade was a 36.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 85,299 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28. Following the completion of the sale, the chief executive officer owned 127,881 shares in the company, valued at $29,504,704.32. This trade represents a 40.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 318,222 shares of company stock valued at $74,068,068. 5.63% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on NTRA. Barclays upped their price objective on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. UBS Group upped their price target on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Robert W. Baird raised their price objective on Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Finally, BTIG Research lifted their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.